ArticleFrontiers in digital health2025
A hybrid PSO-AVOA framework for patient-reported drug prioritization with enhanced exploration and exploitation.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patient-generated drug reviews are becoming increasingly available and serve as a rich source for computational drug prioritization. Methods: In this study, we developed a Hybrid Particle Swarm-Enhanced African Vulture Optimisation Algorithm (Hybrid PSO-EAVOA) that fosters the development of better balances between the exploration and exploitation of which the framework uses the improved opposition-based learning, Levy flights, and elite preservation approaches. In the framework, multiple evaluation criteria are accommodated, recovering value in the form of an overall single-objective optimization scheme, where effectiveness, side-effects, and consistency of reviews were compiled for clinical significance and combined by a weighted-sum fitness function. To validate the experiment using a large-scale dataset of drug reviews obtained from the Drugs Side Effects and Medical Condition dataset sourced from Drugs.com in Kaggle. Results: Hybrid PSO-EAVOA performed a benchmark comparison against five state-of-the-art metaheuristic algorithms (PSO, EAVOA, WHO, ALO, and HOA) using varying iterations as runs. In each comparison, Hybrid PSO-EAVOA achieved superior or better convergence speed, robustness, and quality of solutions. Discussion: The specific method of weighted-sum aggregation was used in this study, the framework offered could be easily compatible with other forms of aggregation. Hybrid PSO-EAVOA demonstrates strong potential for broader application in fields such as pharmacovigilance, clinical decision support, and drug re-purposing. The dataset is publicly available on Kaggle Drugs Side Effects and Medical Condition and all source code for parameter settings and preprocessing scripts is publicly available at the GitHub repository https://github.com/suruthi-m/Hybrid_PSO_EAVOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.